Anixa Biosciences (ANIX) Long-Term Debt Issuances (2013 - 2014)
Anixa Biosciences' (ANIX) quarterly Long-Term Debt Issuances came in at $3.5 million in Q1 2014, up 98.3% YoY from $1.8 million in Q1 2013, and up 98.3% on a QoQ basis from $1.8 million in Q1 2013.
Anixa Biosciences (ANIX) Long-Term Debt Issuances (2013 - 2014) Analysis & Trends
Anixa Biosciences (ANIX) has 2 years of Long-Term Debt Issuances data on file, last reported at $3.5 million in Q1 2014.
- Quarterly Long-Term Debt Issuances rose 98.3% year-over-year to $3.5 million in Q1 2014, while the trailing twelve-month figure through Oct 2014 was $3.5 million (up 98.3% YoY) and the FY2014 annual result came in at $3.5 million, up 98.3% from the prior year.
- Long-Term Debt Issuances rose to $3.5 million in Q1 2014, from $1.8 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $3.5 million in Q1 2014 to a low of $1.8 million in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2014 | 3.50 Mn |
| Jan 31, 2014 | 3.50 Mn |
| Jan 31, 2013 | 1.77 Mn |
| Jan 31, 2013 | 1.77 Mn |